The effects of edaravone in ketamine-induced model of mania in rats
Filiz Civil Arslan, Ahmet Tiryaki, Mehmet Yıldırım, Evrim Özkorumak, Ahmet Alver, İlkay Keleş Altun, İmran İnce, Öznur Gedikli
Acta neurobiologiae experimentalis 2016 DOI: 10.21307/ane-2017-019 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal experiment Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Edaravone Lithium chloride Ketamine |
| Dose | Edaravone 18 mg/kg; lithium chloride 47.5 mg/kg, i.p.; ketamine 25 mg/kg, i.p., 8 days |
| Duration | 8 days of ketamine treatment |
| Measures | Open-field test, Superoxide dismutase (SOD), Catalase (CAT), Thiobarbituric acid reactive substances (TBARS) |
| Topics | Esketamine Ketamine |
| Citations | 12 |
| Key findings | Edaravone at 18 mg/kg did not prevent ketamine-induced hyperlocomotion in rats, while lithium chloride at 47.5 mg/kg did. Edaravone and lithium chloride non-significantly reduced ketamine-associated increases in SOD and CAT activity in hippocampus and prefrontal cortex, with no change in TBARS levels. |
Abstract
Bipolar disorder is a chronic disease characterized by recurring episodes of mania and depression that can lead to disability. This study investigates the protective effects of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a drug with well-known antioxidant properties, in a model of mania induced by ketamine in rats. Locomotor activity was assessed in the open-field test. Superoxide dismutase (SOD), catalase (CAT) and thiobarbituric acid reactive substances (TBARS) levels were measured in order to evaluate oxidative damage in the rat hippocampus and prefrontal cortex. Increased locomotor activity (hyperlocomotion) was observed at the open-field test with ketamine treatment (25 mg/kg, i.p., 8 days). Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47.5 mg/kg, i.p., positive control) did prevent hyperlocomotion. Edaravone and lithium chloride treatments were found to reduce the increase in SOD and CAT activity following ketamine administration in a non-significant manner but caused no change in TBARS levels.
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |
Citations in the library
Cited by 3
- Overlap and Divergence in Ketamine and Lithium Response in Bipolar Disorder: A Scoping Review Pharmaceuticals November 3, 2025
- Psychosis: The Utility of Ketamine as a Pharmacological Model of Psychotic-like Symptoms in Rodents: A Review of Dosage Regimens Biology January 25, 2026
- Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine. Pharmacology, Biochemistry, and Behavior October 2018